Related Experiment Videos
Reduction of urinary basic fibroblast growth factor using pentosan polysulphate sodium
J W Barrington1, S Fulford, L Fraylin
1Department of Urology, Cardiff Royal Infirmary, UK.
British Journal of Urology
|July 1, 1996
Summary
Pentosan polysulphate sodium (PPS) significantly reduced urinary basic fibroblast growth factor (bFGF) in patients after enterocystoplasty. This treatment also improved patient quality of life, particularly mucus production.
Area of Science:
- Urology
- Biochemistry
Background:
- Basic fibroblast growth factor (bFGF) plays a role in bladder conditions.
- Enterocystoplasty can lead to altered urinary profiles.
Purpose of the Study:
- To investigate the efficacy of pentosan polysulphate sodium (PPS) in reducing urinary bFGF levels.
- To assess the impact of PPS on patient symptoms following clam enterocystoplasty.
Main Methods:
- A randomized, placebo-controlled trial involving 41 patients with clam enterocystoplasty.
- Patients received either oral PPS (200 mg thrice daily) or placebo for 6 weeks.
- Urinary bFGF levels were measured pre- and post-treatment; symptom assessment via questionnaire.
Main Results:
- A statistically significant reduction in urinary bFGF was observed in the PPS group (P = 0.0251).
- No significant reduction in bFGF was found in the placebo group (P = 0.235).
- Patients receiving PPS reported symptomatic improvement, notably in mucus production.
Conclusions:
- Pentosan polysulphate sodium (PPS) demonstrates potential in lowering urinary bFGF levels.
- PPS may benefit patients with bladder tumors or those who have undergone enterocystoplasty.
- The study suggests PPS can enhance the quality of life for patients with clam enterocystoplasty.